BioCentury
ARTICLE | Finance

Breathe in, cash out

How a new CEO and a big series A could take Genoa to value inflection

May 19, 2017 6:07 PM UTC

By installing a proven CEO and ponying up sufficient cash to clear Phase II development, Genoa Pharmaceuticals Inc.’s investors believe the company is primed to reach value inflection.

Genoa raised $62 million in a series A financing on May 15. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Novo A/S, RiverVest Venture Partners and TPG Biotech also participated...

BCIQ Company Profiles

Avalyn Pharma Inc.